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ABSTRACT  
Cancer remains a global killer alongside cardiovascular disease. A better understanding of 
cancer biology has transformed its management with an increasing emphasis on a 
personalized approach, so-called ‘precision cancer medicine’. Imaging has a key role to play 
in the management of cancer patients. Imaging biomarkers that objectively inform on tumor 
biology, the tumor environment, and tumor changes in response to an intervention 
complement genomic and molecular diagnostics. In this review we describe the key 
principles for imaging biomarker development and discuss the current status with respect to 
magnetic resonance imaging (MRI).  
 
Keywords: Magnetic resonance imaging; imaging biomarkers; oncology; precision 
medicine 
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INTRODUCTION 
Cancer affects 14.1 million new patients yearly and is the second most common killer 
disease worldwide (1). Clinicians have long recognized that cancer represents a very 
heterogeneous disease. Patients with the same clinical presentation, tumor type and stage 
may respond very differently to the same therapies and have different oncological 
outcomes. A better understanding of the extent of the genomic and molecular 
heterogeneity within cancers, as demonstrated in renal cell cancer (2), has led to a 
refocussing of clinical management in recent years from a global to a more targeted 
approach (3). Currently cancer therapies aim to be personalized to the patient’s cancer, 
either to cure where there is limited disease, or to extend progression-free survival where 
disease is advanced yet maintaining a good quality of life, so-called ‘precision cancer 
medicine’.  
The US Food and Administration (FDA) approval of Bevacizumab in 2004 for first line 
metastatic colorectal cancer, after a Phase III trial demonstrated an improvement in median 
progression free survival (PFS) of 4 months (4), has paved the way for an increasing number 
of licensed molecular targeted therapies. These include targeted HER-2 (human epidermal 
growth factor receptor 2) therapy (trastuzumab) for HER-2 overexpressing breast cancer 
and gastric/gastro-oesophageal cancer; targeted EGFR (epidermal growth factor receptor) 
therapy (cetuximab) for RAS wild type colorectal cancer; targeted EGFR therapy (gefitinib or 
erlotinib) for EGFR mutated non-small cell lung cancer; crizotinib for ALK (anaplastic 
lymphoma kinase) gene rearrangement non-small cell lung cancer (present in approximately 
5% of adenocarcinomas); and multikinase inhibitors (pazopanib, sorafenib, sunitinib) or 
mTOR inhibitors (everolimus) for advanced renal cell cancer.  
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Trials of these therapies have highlighted the need for better diagnostics to support patient 
stratification for therapy as well as a rethink of how we gather evidence for novel 
therapeutics that may only work for a subgroup of patients. There has been burgeoning 
development of precision diagnostics as a consequence. For single agents targeted to 
clearly defined genetic 'driver' alterations, companion diagnostics improve the selection 
of patients for therapy e.g. HER-2 expression to guide trastuzumab therapy and MGMT 
methylation to guide temozolomide therapy. There has also been increasing interest in 
genomic analysis to guide therapy with the move from single to multi-agent regimens and 
also to improve prognostication e.g. Oncotype DX in breast cancer that predicts the 
likelihood of recurrence from a 21 gene signature as well as the likelihood of response to 
chemotherapy.  
While the advantages of genomic analysis and molecular analysis to improve patient 
stratification and to assist drug development is clear, in practice there have been continuing 
challenges to implementation. Some putative biomarkers may be invalid, as shown with 
EGFR expression for cetuximab (5). Cancers are also temporally and spatially 
heterogeneous, i.e. a biopsy or assay may only reflect a moment in time, or one of a number 
of lesions. This plasticity has been a reason for mixed responses to therapies and the 
development of therapy resistance during previously effective targeted therapy (6). There 
may also be issues such as suboptimal methodology, challenging assays, validation, 
regulatory issues and governance or cost that are a challenge for multicentre clinical trials.  
Imaging still has an important role to play in personalized cancer medicine (7).  Imaging is 
performed widely for the detection and characterisation of cancer, for staging, for 
monitoring therapy, for detecting disease recurrence, or surveillance; imaging biomarkers 
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hold great potential for optimizing patient care. The role of magnetic resonance imaging has 
evolved within oncological practice in recent years. Previously reserved as an adjunctive 
problem solving tool, the primary use of magnetic resonance imaging (MRI) has increased, 
such that MRI is now the primary imaging assessment tool for many cancers and plays an 
important part in management decisions. It is the initial imaging modality for diagnosing 
prostate cancer and myeloma; for staging rectal, cervical and endometrial cancer; for 
response assessment in hepatocellular cancer. In this review we will describe what 
constitutes an imaging biomarker, the principles of imaging biomarker development and the 
current status of imaging biomarkers with respect to MRI. 
WHAT CONSTITUTES A BIOMARKER?  
The term ‘biomarker’ refers to a characteristic that is measured objectively, as an indicator 
of normal biological processes, pathological changes, or response to an intervention (8). It 
includes molecular, histologic, radiographic, or physiologic characteristics. In terms of 
imaging, this may include anatomical, functional and molecular characteristics (7). The 
advantages of imaging are its versatility, its widespread usage, its relatively non-invasive 
nature (facilitating whole body imaging as well as longitudinal studies in individuals, thus 
capturing spatial and temporal heterogeneity) and its inherently quantitative nature. 
Imaging biomarkers may reflect a general cancer hallmark e.g. proliferation, metabolism, 
angiogenesis, apoptosis; specific molecular interactions; or agnostic features (9). Imaging 
biomarkers in cancer patients include biomarkers for detection (the identification of 
disease), prediction (the prediction of risk of disease or therapeutic outcome), 
prognostication (the prediction of oncological outcome) and response assessment (the 
evaluation of change with therapy). A number of imaging biomarkers are well established in 
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clinical practice. Examples include staging with the American Joint Committee on Cancer 
(AJCC) TNM (tumor, node, metastasis) staging system (a prognostic biomarker) and 
objective response assessment by RECIST (Response Evaluation in Solid Tumours) (10) in 
clinical trials (a response biomarker). 
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IMAGING BIOMARKERS: FROM DISCOVERY TO CLINICAL PRACTICE 
For new potential imaging biomarkers several steps, often in parallel and complementary to 
each other, need to be undertaken for translation into clinical practice. These can be divided 
into the following phases following discovery: development and evaluation, validation, 
implementation, qualification and utilization essentially crossing 2 main translational gaps, 
translation into patients and translation into practice (Figure 1).  
In the initial phase including development, evaluation and validation, the aim is to ensure 
that the potential biomarker is robust and fit for purpose. Technical validation includes 
assessment of accuracy, precision, repeatability, and reproducibility across single and 
multiple centres; biological and clinical validation ensure that the biomarkers are linked to 
tumor biology, outcome variables and thus of actual value in guiding decision-making in 
patients. During this phase initial health economic analysis may also be undertaken to 
identify if there are cost barriers to implementation. Once the biomarker is established, it 
should be reliable enough to be implemented in clinical trials to test research hypotheses.   
During the next phase, qualification of the biomarker may also be undertaken in large 
prospective trials. Qualification aims to confirm that the biomarker is associated with the 
clinical end-point of interest and aims to demonstrate cost effectiveness and health impact. 
This supportive evidence is key to the translation into clinical practice and widespread 
utilization. Key recommendations have been proposed in a recent consensus article (11).  
ADVANTAGES OF MRI AS AN IMAGING BIOMARKER 
Ideally, there are a number of characteristics an imaging biomarker should have (Table 1). 
MRI has many advantages including its superior soft tissue contrast, high spatial resolution; 
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its ability to obtain multiple contrasts in a single examination; and its ability to assess 
physiology e.g. vascularisation, oxygenation, diffusion. Assessment of the molecular 
environment is also achievable albeit at a lower sensitivity compared to positron emission 
tomography (PET). A number of MRI biomarkers are already established or well on their way 
to being established in clinical practice for oncological assessments (Table 2). These include 
BI-RADS (breast imaging reporting and data system) (12), LI-RADS (liver imaging reporting 
and data system) (13, 14), and PI-RADS (prostate imaging reporting and data system) (15) 
for the diagnosis of breast, hepatocellular cancers, and prostate, respectively; in addition to 
TNM staging and RECIST response evaluation. Quantitative biomarkers that have crossed 
the first translational gap and are being used to test hypotheses in research studies and 
clinical trials include vascular parameters such as initial area under the gadolinium curve 
(iAUGC) or transfer constant (Ktrans) from dynamic gadolinium enhanced (DCE) contrast 
imaging and apparent diffusion co-efficient (ADC) from diffusion weighted MRI (Table 2).  
MORPHOLOGY BASED MRI BIOMARKERS 
Current morphology based cancer biomarkers utilize the multiple contrasts and high spatial 
resolution of MRI. T2-weighted and T1-weighted sequences are part of every cancer 
protocol. T2-weighting highlights structures with a longer T2 relaxation time. Thus organs 
with a high water content, e.g. bladder, appear of high signal on T2-weighted imaging while 
cancers typically appear of intermediate signal. T2-weighted image contrast is encoded by a 
long echo time (TE) and long repetition time (TR). Typically, 2D imaging is performed in axial, 
sagittal, and/or coronal planes using a fast/turbo spin echo sequence. 3D imaging can be 
performed using a 3D T2w-TSE with optimised flip angle evolution along the echo train (e.g. 
Siemens SPACE, Philips VISTA, GE CUBE). T1-weighting highlights structures with a short T1 
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e.g. fat, melanin. T1-weighted image contrast is encoded by a short TE and short TR. T1w-
MRI is acquired with fast gradient echo sequences in 2D (Siemens FLASH, Phillips FFE, GE 
GRE) or 3D (Siemens VIBE, Philips THRIVE, GE Lava).  
Diagnostic biomarker 
A key example of a recently established diagnostic biomarker is PI-RADS (Prostate Imaging 
Reporting and Data System) in suspected prostate cancer, currently on version 2.0 (15), 
utilizing multi-parametric MRI. The PROMIS trial (16, 17) has recently published its findings 
confirming a role for multi-parametric MRI in the diagnostic pathway of patients with 
suspected prostate cancer. This enrolled 740 men, 576 of whom underwent 1·5 Tesla multi-
parametric MRI followed by both TRUS-biopsy and template prostate mapping biopsy. On 
template prostate mapping biopsy, 408 (71%) of 576 men had cancer with 230 (40%) of 576 
patients clinically significant. For clinically significant cancer, multi-parametric MRI was more 
sensitive (93%, 95% CI 88-96%) than trans-rectal ultrasound (TRUS) biopsy (48%, 42-55%; 
p<0·0001). Using multi-parametric MRI to triage men might allow 27% of patients to avoid a 
primary biopsy and improve detection of clinically significant cancer. Using a structured 
reporting scheme such as PI-RADS standardizes practice, provides an objective score of the 
likelihood of disease, and helps direct targeted biopsy. Risk scores to assess the likelihood of 
clinically significant cancer are defined as PI-RADS 1: very low, PI-RADS 2: low, PI-RADS 3: 
intermediate, PI-RADS 4: high, to PI-RADS 5: very high. A meta-analysis has revealed overall 
high sensitivity and specificity of 0.74 and 0.88 respectively for prostate cancer detection 
with PI-RADS (18, 19). MRI is performed with a multi-parametric acquisition of at least T2-
weighted and diffusion weighted sequences (20) (Figure 2). This combines high resolution, 
high soft tissue contrast of T2-weighted imaging with the diffusion weighted imaging 
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sensitivity for cancer(21). Additional dynamic contrast enhanced sequences provide 
information of wash-in and wash-out characteristics and may provide additional diagnostic 
value. A recent study has demonstrated an increase in the probability of cancer detection of 
16%, 16%, and 9% for PI-RADS category 2, 3, and 4 lesions respectively with DCE-MRI (22).  
Prognostic biomarker: Staging 
Staging is an important imaging biomarker for patient stratification. MRI is the primary 
staging modality for a number of cancers including rectal cancer. In addition to TNM-Stage 
grouping, which provides an indication of relative 5-year overall survival [Stage I (localised, 
T1/2), node negative: 95%; versus Stage IV (metastatic, any T,N): 11%], MRI also has a 
predictive role in terms of likely involvement of the resection margin and progression free 
survival (23-25) (Figure 3). 
Response biomarker: RECIST 
RECIST criteria provide a standardized, objective assessment of response to therapy in 
clinical trials (10). Classification of response is into 4 categories (complete response, partial 
response, stable disease, progressive disease) based on size change of specified measurable 
target lesions (>1cm) or nodes (>1.5cm short axis) (Table 3). From a regulatory perspective, 
RECIST remains the key response biomarker in clinical trials and is used as a surrogate end-
point. 
VALIDATED MRI BIOMARKERS REQUIRING QUALIFICATION 
Diffusion-weighted MRI 
Apparent diffusion coefficient is a biomarker that has crossed the first translational gap and 
is used to test research hypotheses in clinical trials (26). The biophysical basis of diffusion 
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weighted imaging is the microscopic displacement of water molecules (Δx ≈ 30 μm in Δt = 50 
ms) due to thermal Brownian motion. In cancers the tumour environment restricts this 
motion, thus a measurement of the effective displacement, the apparent diffusion 
coefficient (ADC), gives important microscopic information. Tumor ADC from b-values less 
than 1000s/mm2 effectively provide a measure of the extracellular space; although cell size, 
cell arrangements, cell density, integrity of cell membranes, glandular structures, 
extracellular space viscosity and tortuosity will influence this measurement. Studies have 
correlated ADC with histological grade in a number of cancers (27-30).  
The diffusion image contrast is encoded by using a gradient pair [Stejskal-Tanner gradient 
(26)], which can be either a bipolar gradient pair in gradient echo or the same polarity in 
spin echo. This gradient causes a change in the resonant Larmor frequency of a spin 
isochromat, leading to the following phase accumulation 𝜙 
𝜙 =  ∫ Δ
𝑡
0
𝜔𝑑𝑡′ =  𝛾 ∫ ?⃗?(𝑡′) ∙ 𝑟(𝑡′)
𝑡
0
𝑑𝑡′ 
 
Where ?⃗? is the applied gradient waveform applied for a duration t,   𝑟 ⃗⃗⃗ is the spatial position 
of the spin isochromat, and 𝛾 the gyromagnetic ratio. Thus, spins, which move during the 
application of the gradient pair will not be properly rephased. This loss in phase coherence 
secondary to spatial displacement causes a reduction in the signal. For random spin 
diffusion motion in an image voxel, this signal cancellation is related to the variance of the 
Gaussian phase distribution ø2 and the product bD: 
𝑆 = 𝑆0𝑒
−〈𝜙2〉 = 𝑆0𝑒
−𝑏𝐷 
Where S is the diffusion weighted signal and S0 is the signal without diffusion weighting. 
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Thus, the degree of attenuation depends on the dimensionless product of the diffusion 
coefficient D (in mm2/sec) and the b-value (in sec/mm2). The b-value is used to control the 
diffusion-weighted contrast with higher diffusion weighting at higher b-values. Typically, b-
values of 0-1500s/mm2 are applied in clinical practice and ADC is obtained from 
monoexponential fitting of the signal loss (Figure 4). In practice, other factors contribute to 
signal loss including T2-relaxation and bulk motion. In a given voxel, ADC will reflect the 
relative contribution of the different compartments.  
A number of studies have evaluated ADC as a response biomarker in a number of tumor 
types across different therapies in research studies including the multicentre setting. These 
studies have shown that a common pattern is an increase in ADCmean to a varying extent 
with different therapies. This may occur within days of starting treatment; a higher change 
in ADCmean is also associated with pathological good response (31-39).  
The variability of ADC in clinical studies has been reported to be relatively low at ≤15% (40) 
and in ice-water phantom studies as low as 3% (41). Nevertheless, there are considerations 
to be made in the trial setting (42) and technical challenges to acquiring robust diffusion 
weighted biomarkers and qualification as a biomarker(26). TR should be sufficiently long to 
avoid underestimation of ADC due to T1 saturation effect; TE should be minimized to 
achieve better SNR, to minimize motion and susceptibility artefacts. Good fat suppression is 
required to minimize ghosting artefacts; Short tau inversion recovery (STIR) may be 
preferred to spectral presaturation attenuated by inversion recovery (SPAIR) or chemical 
shift selective water only excitation techniques, where a large field of view is necessary at 
1.5T as STIR is less sensitive to B0 field inhomogeneities. Geometric distortion and 
susceptibility artefacts caused by eddy currents related to EPI may be improved by 
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shortening the echo train length, e.g. through adapting the receiver bandwidth to reduce 
the echo spacing, use of parallel imaging, zoomed excitation or readout segmented imaging.  
 
Dynamic contrast enhanced MRI 
Dynamic contrast enhanced (DCE) MRI refers to the rapid acquisition of a time series of T1w 
images before, during and after intravenous administration of a gadolinium-based contrast 
agent. Gadolinium contrast agents are small hydrophilic molecules with a short circulation 
half-life, typically <1hour. These contrast agents shorten the T1-relaxation rate thus cause 
signal enhancement related to the delivery and leakage rate of contrast agent within the 
tissue of interest, providing a surrogate measure of angiogenesis.  
While qualitative assessment of curve shape is an established imaging biomarker e.g. for the 
evaluation of suspected breast and prostate cancer; the use of quantitative vascular 
parameters remains in the domain of clinical trials. In terms of qualitative assessment, three 
distinct curve shapes are recognised: Type 1) slow rising enhancement (benign); Type 2) 
rapid enhancement with a plateau (may be malignant); and Type 3) rapid enhancement 
followed by rapid wash-out (malignant). 
For assessing quantitative parameters, baseline T1 mapping is required usually with a dual 
flip angle 3D T1-weighted spoiled gradient recalled echo acquisition (e.g. 2°/18°) with other 
parameters remaining constant.  
The baseline T1 value (T10) is estimated from fitting the signal intensity of the images 
acquired with different flip angles to the following equation:  
𝑆 =
𝑆0(1 − 𝐸1)𝑠𝑖𝑛(𝛼)
1 − 𝐸1
∗𝑐𝑜𝑠(𝛼)
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Where S is acquired T1-weighted signal, α represents the applied flip angle in each 
acquisition, S0 is the T1 fully relaxed signal, and 𝐸1 = 𝑒
−𝑇𝑅
𝑇10 , where TR is the sequence 
repetition time. Following contrast agent administration, typically 0.1mmol/kg body weight, 
a dynamic acquisition for up to 5 minutes yields a temporal resolution in the order of 3-5s 
between acquisitions. Contrast agent concentration may be estimated by the following 
equation: 
1
𝑇1(𝑡)
=
1
𝑇10
+ 𝑟1𝐶 
where T1(t) represents the T1 change over time due to the contrast agent, T10 represents 
the T1 of the tissue at baseline and r1 represents the T1 relaxivity of the contrast agent and 
C represents the unknown contrast concentration.  
The Tofts and Kermode model (43) is applied most commonly to determine Ktrans (a product 
of flow and transfer permeability)  
𝑑𝐶𝑡(𝑡)
𝑑𝑡
= 𝐾𝑡𝑟𝑎𝑛𝑠𝐶𝑝(𝑡) − 𝑘𝑒𝑝𝐶𝑡(𝑡) 
where 𝐶𝑡(𝑡)and 𝐶𝑝(𝑡)represent the contrast agent concentration in tissue and plasma as 
function of time respectively, Ktrans represents transfer constant, kep represents the rate 
constant; or as an extended model to account for the contrast agent in the vasculature, 
when vascular volume cannot be neglected.  
𝐶𝑡(𝑡) = 𝑣𝑝𝐶𝑝(𝑡) +  𝐾
𝑡𝑟𝑎𝑛𝑠 ∫ 𝐶𝑝 (𝑡
1)𝑒𝑥𝑝 (
−𝐾𝑡𝑟𝑎𝑛𝑠(𝑡 − 𝑡1)
𝑣𝑒
)
𝑡
0
𝑑𝑡1 
where 𝐶𝑡(𝑡) and 𝐶𝑝(𝑡) represent the contrast agent concentration in tissue and plasma 
respectively, Ktrans represents transfer constant, kep represents the rate constant; vp 
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represent the fractional plasma volume; and ve the fractional extracellular extravascular 
volume. 
In the last 15 years, over 110 studies in 2268 patients have utilized quantitative DCE-MRI as 
a biomarker in clinical studies and trials reflecting the use of DCE-MRI to assess vascular 
activity in drug development (44), in particular to assess the effect of anti-angiogenic or 
anti-vascular therapy (Figure 5). Consistent reduction in the initial area under the 
gadolinium curve (iAUGC) and Ktrans have been found for a number of therapies including 
VEGF-targeted agents (bevacizumab) and multikinase inhibitors (pazopanib, sunitinib, 
sorafenib), as early as a few hours after dosing. 
 
Nevertheless, the variability of Ktrans in clinical studies remains a major issue (>50%), and 
baseline reproducibility has been utilized in clinical trials on an individual basis in order to be 
able to determine whether the measured change is related to therapeutic effect. Accurate 
determination of the arterial input function (AIF) which characterizes contrast agent arrival 
in a feeding blood vessel within the tumor remains a challenge to accurate quantification. As 
an alternative to subject-specific direct measurement of AIF (subject to flow artefacts, 
nonlinear effects of high contrast agent concentrations, and partial volume effects), 
population-based AIFs (45) or reference tissue based methods (46) have been advocated. 
Accurate T1-mapping also remains a challenge, as B1 inhomogeneity, particularly at 3T and 
higher field strengths limit the accuracy of T1-estimates derived from the typically employed 
VFA technique. Recent developments propose to include B1+ for T1-mapping (47). To 
overcome the challenge of achieving both, high spatial and temporal resolution for the DCE 
data acquisition, advanced methods have been proposed, such as combining parallel 
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imaging, compressed sensing and non-cartesian sampling (48), view sharing (49), and 
motion compensation (50).  
 
EMERGING MRI BIOMARKERS 
Further emerging quantitative biomarkers are undergoing evaluation (Table 4), related to 
the following techniques: intravoxel incoherent motion (IVIM), diffusion kurtosis imaging, 
blood and tissue oxygenation level dependent MRI (BOLD/TOLD), MR elastography, and 
relaxometry imaging. There has also been growing interest in extracting additional agnostic 
features from standard and quantitative MRI sequences, so called radiomics (9).  
Pseudodiffusion and intravoxel incoherent motion 
Bulk water motion in capillaries can also cause phase dispersion in diffusion weighted MRI 
(51, 52). The loss in signal is similar to that seen with true diffusion and more marked at low 
b-values. Diffusion weighted MRI always measures both, but relative contribution depends 
on the choice of b-values. The contribution of true diffusion and perfusion towards signal 
loss can be defined as follows:  
𝑆(𝑏) = (1 − 𝑓𝑣)𝑒
−𝑏𝐷 + 𝑓𝑣𝑒
−𝑏𝐷∗ 
Where S is the acquired diffusion-weighted signal, b represents the b-value, fv represents 
the fractional volume of flowing water molecules within capillaries; (1-Fv) is the fraction of 
molecules undergo true diffusion; D represents tissue diffusion co-efficient and D* the 
pseudo-diffusion co-efficient. D* the pseudo-diffusion coefficient associated with blood flow 
is about 10x10-3 mm2/sec in the brain and 70x10-3 mm2/sec in the liver compared to D which 
is 1x10-3 mm2/sec. 
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Assessing fv and D* may be feasible for patients with poor renal function, an allergy 
precluding intravenous administration of contrast agent or at high-risk of developing 
nephrogenic systemic fibrosis (53).  
However, one of the issues highlighted to date is the poor test-retest variability of f and D* 
(54), in the order of >100% in some cancers e.g. rectal (55). There also appears some 
contention as to technical/biological correlates: while some studies have shown a 
relationship between IVIM and DCE-MRI parameters (56-58), others have not in some 
cancers e.g. hepatocellular carcinoma (59). One also has to be aware that flow from 
glandular secretions e.g. pancreas may be difficult to separate from micro-capillary 
perfusion. A potential application is as a diagnostic biomarker, where current 
characterisation may be a challenge e.g. pancreas (60, 61).  
Apparent diffusional kurtosis  
Diffusion kurtosis imaging characterizes non-Gaussian diffusion behaviour at high b-values 
ranging from 1000 – 3000 sec /mm2. A polynomial decay model is fitted to an acquisition 
using at least 3 b-values to obtain Dapp..and Kapp representing the heterogeneity of the 
cellular microstructure. The diffusion signal Si for a given b-value bI is given by 
𝑆𝑖 = 𝑆0 ∗ 𝑒
𝑏I𝐷𝑎𝑝𝑝+
1
6𝐷𝑏I
2𝐷2𝑎𝑝𝑝𝐾𝑎𝑝𝑝
 
Where S0 is the signal without diffusion weighting, Kapp is the apparent diffusional kurtosis 
and Dapp is the diffusion co-efficient. Kapp reflects the signal curvature away from a 
monoexponential fit. The rationale proposed for assessing kurtosis is that it may better 
reflect the tumor intracellular microstructure (62, 63) although it will also be influenced by 
extracellular properties. Higher kurtosis may be noted where there are higher intracellular 
interfaces, for example, increased nuclear-cytoplasmic ratio of tumor cells (64). Preliminary 
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studies in prostate cancer have suggested potential as a diagnostic biomarker (65), e.g. to 
improve characterisation (grading) (66, 67), though not all studies have confirmed additional 
advantages over monoexponential ADC (68, 69). Studies have also suggested its potential as 
a response biomarker. A study in hepatocellular carcinoma has suggested that Kapp performs 
better than ADC in detecting viable disease post-treatment (70). 
Tumor elasticity and viscosity  
Magnetic resonance elastography (MRE) quantifies the viscoelastic properties of tissue by 
assessing its elastic response to an applied force, similar to palpation in clinical practice. The 
applied force consists of harmonic mechanical waves, ranging typically between 20 and 80 
Hz in frequency and propagated into the human body by a vibrating transducer applied to 
the body surface. The consequent tissue motion is captured using rapid motion-sensitive 
MRI sequences. Through mathematical inversion algorithms, the local shear wave 
properties can be derived from the periodical variations in MRI signal; the local viscoelastic 
parameters (elasticity and viscosity) are then calculated using the complex shear modulus 
equation (71). The underpinning experimental observation for the application of MRE to 
cancer is that malignancy increases stiffness through collagen deposition in the extracellular 
matrix and raised interstitial pressure levels from its abnormal vasculature (72). MRE has 
shown promising potential for the characterization of focal lesions (benign vs. malignant) in 
multiple organs, including the liver (73), breast (74), pancreas (75) and kidney(76). It may 
also serve as a potential biomarker of treatment resistance. 
Tumor oxygenation 
Tumor oxygenation may be measured indirectly by BOLD and TOLD-MRI techniques. With 
BOLD MRI, endogenous hemoglobin acts as a paramagnetic contrast agent which increases 
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the transverse relaxation rate (R2*) in blood and surrounding tissue. R2* is measured from 
multiple spoiled gradient recalled echo images with increasing echo times. R2* is calculated 
from the gradient of a straight line fitted to a plot of ln-signal intensity to TE. Higher R2* 
reflects higher deoxyhemoglobin levels and lower blood oxygenation. R2* may have a role 
as a response biomarker. One study has shown that R2* is inversely correlated to blood 
volume and increases in breast cancer treated with 2 cycles of neoadjuvant chemotherapy 
with greater changes in patients with pathological response (77). However, BOLD 
measurements will be affected by the underlying tissue relaxivity and will be affected by 
hemorrhage and susceptibility artefacts.  
 
With TOLD MRI the longitudinal relaxation rate (R1) is measured. R1 is sensitive to changes 
in the O2 dissolved in blood plasma and interstitial fluid. When a hyperoxic gas is inhaled, 
the excess oxygen dissolved will result in a higher R1 value. A positive change in R1 will 
identify areas with fully saturated haemoglobin. Areas where there is no positive change in 
R1 may reflect regions of hypoxia particularly if perfusion is present. Current approaches are 
focussing on the feasibility of combining R2* and R1 measurement with oxygen challenge to 
assess tumor oxygenation (78).  
 
Quantitative MRI with or without exogenous contrast agents 
In current clinical practice diagnosis based on MRI primarily relies on the qualitative 
assessment of images. In contrast, quantitative measurements of tissue properties with or 
without endogeneous contrast agents may provide more accurate and reproducible 
information. Without the use of exogenous contrast agents, relaxometry yields quantitative 
measurement of intrinsic tissue relaxation times T1 and T2 (79)(80)(81)(82), T2*, proton 
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density. In addition, important molecular information about tumour physiology and 
metabolism (“tumour microenvironment”) may be obtained from MR spectroscopy (MRS) 
(83)(84)(85)(86)(87)(88), Chemical Exchange Saturation Transfer Imaging (CEST) (89) and 
Amide Proton Transfer (APT) (90). Further, relaxometry with exogenous contrast agents 
enables imaging of perfusion, using either gadolinium-based contrast agents (91) and 
dynamic T1w- (DCE) as discussed previously or T2*w-MRI (dynamic susceptibility contrast-
enhanced (DSC)). Superparametric iron oxide (SPIO) nanoparticles in combination with T2-w 
and T2*-w MRI have been developed as imaging probes for targeted molecular MRI, cell 
tracking, and drug delivery (“theranostics”)(92)(93)(94). Alternatively, highly specific, 
background-free imaging can be achieved via non-proton imaging using e.g. F-19 
(95)(96)(97) or hyperpolarized agents C-13 (98, 99). However, these require hardware 
modifications to be able to image the non-proton frequencies.  
Novel quantitative methods have also been proposed to acquire several tissue properties at 
once (100) (101). A method termed “MR-fingerprinting” utilizes a (pseudo) randomized 
acquisition sequence to encode a tissue specific “Fingerprint” into a MR time series signal 
(102). This has recently also been adapted and applied to cancer imaging (103)(104)(105). 
Finally, to achieve its full potential, a key challenge of mp-MRI is standardisation across 
multiple platforms, which involves the use of phantoms and careful review of 
implementation(106). 
 
Radiomics  
Radiomics is an evolving area in medical imaging whereby a large number of features are 
extracted and interpreted using bioinformatic approaches (9, 107). The underlying rationale 
for radiomics lies in the supposed relationship between extracted image parameters and 
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tumor molecular phenotype and / or genotype. It is known that genotypic heterogeneity 
contributes to divergent tumor biological behavior including poor treatment response and a 
more aggressive phenotype. Therefore there is growing interest in using imaging radiomic 
signatures either alone or in combination with other clinical or -omics data, e.g. 
radiogenomics to improve tumor phenotyping (prognostication), to allow tumor sub-regions 
with different biological characteristics that may contribute to treatment resistance to be 
identified/segmented for therapies, and for the prediction and evaluation of therapies. 
Radiomic studies have used a number of techniques including statistical methods 
(histogram; gray-level co-occurrence matrix (GLCM); gray-level difference matrix (GLDM), 
run length matrix (RLM), gray level size zone matrix (GLSZM) and neighborhood gray tone 
difference matrix (NGTDM)) with or without Gaussian or Wavelet transformation; and 
fractal based methods across different sequences including T2-weighted, diffusion-weighted 
and dynamic contrast enhanced sequences. Initial radiogenomic studies including MRI have 
been performed in breast cancer (108-110) renal cell carcinoma(111) and glioma(112, 113). 
Variable reproducibility has been shown across different classes of features (114) and 
further validation work is still required for radiomic biomarkers.  
 
CONCLUSION 
 Precision cancer medicine remains a desirable goal for cancer care.  
 MRI offers many advantages as a diagnostic, prognostic, predictive or response 
biomarker in cancer given its capability of multiple contrast and multi-parametric 
quantitative imaging.  
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 A key challenge remains to improve the efficiency of biomarker translation from 
discovery to implementation. Clinical translation for emerging biomarkers remains 
slow.  
 To overcome issues regarding biomarker measurement variability across devices and 
across manufacturers, phantoms for quality assurance, standardization of protocols 
and availability of reference value databases has helped to facilitate this, alongside 
networks and alliances including the Quantitative Imaging Network (QIN) (http:// 
imaging.cancer.gov/informatics/qin), the Quantitative Imaging Biomarker Alliance 
(QIBA) (http://www.rsna.org/qiba/); the Quantitative Imaging in Cancer: Connecting 
Cellular Processes to Therapy (QuIC-ConCePT) (http://www.quic-concept.eu/) 
consortium; and the American College of Radiology Imaging Network (ACRIN). 
 With emerging machine learning approaches, quantitative MRI biomarkers will no 
doubt continue to expand to meet new challenges in the personalized care of 
oncology patients. 
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FIGURE LEGENDS 
Figure 1. Schema highlighting steps taken in developing a potential imaging biomarker 
Figure 2. Multi-parametric prostate MRI demonstrates a left mid gland PI-RADS 5 peripheral 
zone lesion extending beyond the prostate (A: T2-weighted, B: diffusion weighted apparent 
diffusion coefficient map, C: arterial phase dynamic contrast enhanced T1-weighted image). 
Figure 3. T2-weighted axial image demonstrates a T3N1 rectal cancer extending beyond the 
rectal wall but not involving the potential resection margin 
Figure 4. The T2 axial oblique image (A) of a rectal cancer, diffusion-weighted images with 
increasing b-weighting 0 (B),100 (C), 500 (D) and 800 s/mm2(E) and corresponding ADC0-800 
map (F) is shown. Signal loss is demonstrated within the rectal cancer with increasing b-
weighting. The signal loss is greater for normal tissue than for the cancer.   
Figure 5. T2-weighted (A) and corresponding transfer constant maps (Ktrans, B) before and 
after 3 cycles of therapy with an anti-angiogenic and triplet chemotherapy. A decrease in 
tumor vascularization is noted following 3 cycles of therapy. 
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TABLES 
Table 1: Key characteristics and challenges for MRI imaging biomarkers 
Characteristics Challenges for MRI Developments 
Sensitive Signal to noise ratio (SNR) 
Contrast to noise ratio (CNR) 
Spatial resolution 
Artefacts 
New sequences  
Specific & 
biologically 
relevant 
Targeted versus physiological or 
morphological imaging  
Evaluation of more targeted 
imaging e.g. receptor imaging, 
targeted nanoparticles 
Robust Variance among imaging systems, 
manufacturers & practice 
Multi-vendor & multicenter 
involvement to standardize data 
acquisition, reconstruction & 
analysis 
Quantifiable & 
reproducible 
Variance among imaging systems, 
manufacturers & practice 
Advanced acquisition and 
reconstruction to exploit data 
redundancy 
 
Single-sequence MRI to acquire 
several image contrasts in a co-
registered fashion, e.g. MR 
fingerprinting 
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Cost effective  Higher cost compared to 
computed tomography (CT) or 
ultrasound (US) 
Reduction in scanner time with 
faster acquisitions 
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Table 2: Established and validated MRI biomarkers in clinical use 
Biomarker  Characteristic MRI sequence 
Established biomarkers in clinical practice 
Detection & Characterisation 
BI-RADS (Breast Imaging 
Reporting and Data System 
PI-RADS (Prostate Imaging 
Reporting and Data 
System) 
LI-RADS (Liver Imaging 
Reporting and Data System 
Lesion morphology T2-weighted, T1-weighted, 
diffusion weighted, post 
contrast enhanced imaging 
Curve shape 
 
 
 
Degree of vascularization Dynamic T1-weighted 
imaging following 
intravenous injection of 
gadolinium-based contrast 
agent 
Staging 
TNM stage  Tumor morphology, 
presence of nodes and 
metastases 
T2-weighted, T1-weighted 
imaging 
± diffusion weighted, post 
contrast enhanced imaging 
Response 
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RECIST (Response 
evaluation criteria in solid 
tumors 
Change in tumor size T2-weighted imaging 
Validated biomarkers in clinical cancer research 
Apparent diffusion co-
efficient (ADC) 
Cellularity Diffusion-weighted imaging, 
at least 2 b-values 
Initial area under the 
gadolinium curve (iAUGC) 
Transfer constant (Ktrans) 
Perfusion 
Permeability 
Dynamic T1-weighted 
imaging following 
intravenous injection of 
gadolinium-based contrast 
agent 
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Table 3. Response categorisation based on changes in target and non-target lesions 
RECIST  
Categorisation Target lesions Non-target lesions 
Complete Response 
(CR) 
 
Disappearance of all target 
lesions (TL). All nodes <10 
mm  i.e. non-pathological 
Disappearance of all non-target 
lesions. All nodes <10 mm i.e. 
non-pathological 
Partial Response 
(PR) 
>30% decrease in the sum of 
TL diameters 
Non CR/PD: Persistence of ≥1 
non-target lesion 
Stable Disease (SD) Neither PR nor PD 
Progressive Disease 
(PD) 
 
> 20% increase in the sum of 
TL diameters. Absolute 
increase of at least 5 mm. 
New lesions 
Unequivocal progression of 
existing non-target lesions 
New lesions 
 
Target lesions: Up to 5 measured, 2 maximum per organ 
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Table 4: Emerging biomarkers undergoing validation in research studies  
Emerging Biomarkers Measure/Biological 
correlate  
MRI sequence 
f, D* Pseudoperfusion Multiple low b-value diffusion 
weighted imaging (Intravoxel 
incoherent motion, IVIM) 
Kurtosis (Kapp) Microstructural complexity Diffusion kurtosis imaging (DKI) 
R2* 
R1 
ΔR2* 
ΔR1 
 
Relaxation rate 
Oxygenation  
Blood oxygenation level 
dependent imaging (BOLD) 
Tissue oxygenation level 
dependent imaging (TOLD) 
± oxygen/carbogen challenge 
Elasticity 
Viscosity 
Tissue mechanics and 
viscoelastic parameters 
Elastography: motion sensitive 
sequence to encode shear wave 
propagation 
Specific metabolites 
e.g. Choline 
Metabolite concentration Spectroscopy 
T1 
T2 
Relaxation time 
Microenvironment 
Multi-echo relaxometry imaging 
Texture features Heterogeneity Any 
 
 
